Ftse Mib
34.452,32
-0,60%
DAX
18.591,25
-0,50%
S&P 500
5.306,04
0,02%
NASDAQ
0,00
0,00%
Bitcoin
67.827,40
-0,68%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Syros Pharmaceuticals Inc (SYRS) Syros Pharmaceuticals Inc (SYRS) Notizie

Syros Pharmaceuticals Inc

SYRS
5,00
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:00:02
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/5/202413:30BWSyros Reports First Quarter 2024 Financial Results and..
14/5/202412:42EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202415:00BWSyros to Participate in Upcoming Investor Conferences
07/5/202413:00BWSyros to Report First Quarter 2024 Financial Results on..
09/4/202413:00BWSyros Receives Fast Track Designation from the FDA for..
02/4/202422:30BWSyros Reports Inducement Grants Under Nasdaq Listing Rule..
27/3/202412:30BWSyros Reports Fourth Quarter and Full Year 2023 Financial..
27/3/202411:57IHMARKETNEWSU.S. Stock Index Futures Point to a Rebound, Oil See..
25/3/202412:00BWSyros Announces Completion of Enrollment of 190 Patients..
20/3/202412:00BWSyros to Report Fourth Quarter and Full Year 2023 Financial..
27/2/202413:00BWSyros to Participate in TD Cowen 44th Annual Health Care..
15/2/202402:56EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202402:22EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202401:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202400:59EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/1/202413:06EDGAR2Form 8-K - Current report
08/1/202413:00BWSyros Highlights Anticipated 2024 Milestones to Deliver on..
02/1/202422:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
26/12/202323:19EDGAR2Form SC 13D/A - General statement of acquisition of..
19/12/202322:59EDGAR2Form 8-K - Current report
19/12/202322:53EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/12/202313:27BWSyros Announces Pricing of $45.0 million Underwritten..
14/12/202322:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202322:12EDGAR2Form 144 - Report of proposed sale of securities
08/12/202322:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202322:00EDGAR2Form 144 - Report of proposed sale of securities
06/12/202313:05EDGAR2Form 8-K - Current report
06/12/202313:00BWSyros Announces Encouraging Initial Data from Randomized..
05/12/202323:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202313:30BWSyros to Participate in Upcoming Investor Conferences
14/11/202313:30BWSyros Reports Third Quarter 2023 Financial Results and..
14/11/202312:47EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:30BWSyros to Report Third Quarter 2023 Financial Results on..
02/11/202321:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202321:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202321:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202321:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/10/202322:15EDGAR2Form SC 13D - General statement of acquisition of beneficial..
02/10/202314:49EDGAR2Form 8-K - Current report
02/10/202314:45BWSyros Announces Planned CEO Leadership Transition and..
07/9/202322:30BWSyros Reports Inducement Grants Under Nasdaq Listing Rule..
11/8/202322:30EDGAR2Form 8-K - Current report
08/8/202313:30BWSyros Reports Second Quarter 2023 Financial Results and..
08/8/202312:53EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/8/202322:30BWSyros Reports Inducement Grants Under Nasdaq Listing Rule..
02/8/202322:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202313:30BWSyros to Report Second Quarter 2023 Financial Results on..
31/7/202322:12EDGAR2Form 144 - Report of proposed sale of securities
21/7/202322:36EDGAR2Form 8-K - Current report
19/7/202302:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: Min: Max:
Chiusura: 5,00

La tua Cronologia

NASDAQ
SYRS
Syros Pharmaceuticals
ASX
EVEN
Energy Ventures
TSXV
BTR
BonTerra Resources
AMEX
EIM
Eaton Vance Municipal
COIN
MGPTUST
MotoGP Fan Token
ASX
QOZSO1
BIT
P08929
Bnp Paribas Issuance
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network